首页> 外文期刊>European urology >Neoadjuvant temsirolimus effectiveness in downstaging advanced non-clear cell renal cell carcinoma
【24h】

Neoadjuvant temsirolimus effectiveness in downstaging advanced non-clear cell renal cell carcinoma

机译:新辅助西罗莫司治疗晚期晚期非透明细胞肾细胞癌的有效性

获取原文
获取原文并翻译 | 示例
           

摘要

A 35-year-old woman presented with a 12-cm right renal mass with retroperitoneal lymph node involvement and pulmonary and bone metastases. Renal mass biopsy revealed an unclassified high-grade non-clear cell renal cell carcinoma (RCC) with eosinophilic cells. Due to the extent of the disease, neoadjuvant temsirolimus was initiated. After 6 wk of treatment, a significant downstaging of the disease and complete disappearance of the metastases were noticed on computed tomography scan. Three months later, a laparoscopic radical nephrectomy and lymphadenectomy was performed. Final pathology confirmed a high-grade non-clear cell RCC, with necrotic changes on lymph node specimens, pT1bN0Mx.
机译:一名35岁的女性患者右肾肿块长12厘米,腹膜后淋巴结受累,发生肺和骨转移。肾活检显示有嗜酸性细胞的未分类高级别非透明细胞肾细胞癌(RCC)。由于疾病的程度,开始使用新辅助剂西罗莫司。经过6周的治疗后,在计算机断层扫描中发现该疾病的病程明显降低,转移灶完全消失。三个月后,进行了腹腔镜根治性肾切除术和淋巴结清扫术。最终病理证实为高度透明细胞RCC,淋巴结标本pT1bN0Mx坏死。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号